{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:43:44Z","timestamp":1792421024636,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"DOI":"10.7759\/cureus.66776","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:25:15Z","timestamp":1723562715000},"source":"Crossref","is-referenced-by-count":2,"title":["Complete Heart Block in a Patient Undergoing Combination Immune Checkpoint Inhibitor Therapy"],"prefix":"10.7759","author":[{"given":"Himara","family":"Koelmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinley","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Feradov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Kotch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018, 359:1350-5. 10.1126\/science.aar4060","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas N","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020, 9:e013757. 10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi J","year":"2021","unstructured":"Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest. 2021, 131:10.1172\/JCI145186","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu JR","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019, 115:854-68. 10.1093\/cvr\/cvz026","journal-title":"Cardiovasc Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-022-00130-5","article-title":"Cardiotoxicity risk factors with immune checkpoint inhibitors","volume":"8","author":"Brumberger ZL","year":"2022","unstructured":"Brumberger ZL, Branch ME, Klein MW, Seals A, Shapiro MD, Vasu S. Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardiooncology. 2022, 8:3. 10.1186\/s40959-022-00130-5","journal-title":"Cardiooncology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36446","article-title":"Two cases of immune checkpoint inhibitor-induced myocarditis with complete atrioventricular block","volume":"15","author":"Kondo H","year":"2023","unstructured":"Kondo H, Kirigaya J, Matsuzawa Y, Hibi K. Two cases of immune checkpoint inhibitor-induced myocarditis with complete atrioventricular block. Cureus. 2023, 15:e36446. 10.7759\/cureus.36446","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101390","article-title":"Immunotherapy-associated complete heart block in a patient with NSCLC: a case report and literature review","volume":"33","author":"Vartanov A","year":"2021","unstructured":"Vartanov A, Kalotra A, Varughese J, Gautam S, Kandel S, Hosmer W. Immunotherapy-associated complete heart block in a patient with NSCLC: a case report and literature review. Respir Med Case Rep. 2021, 33:101390. 10.1016\/j.rmcr.2021.101390","journal-title":"Respir Med Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem JE","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018, 19:1579-89. 10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann LH","year":"2021","unstructured":"Lehmann LH, Cautela J, Palaskas N, et al.. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol. 2021, 6:1329-37. 10.1001\/jamacardio.2021.2241","journal-title":"JAMA Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018, 71:1755-64. 10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power JR","year":"2021","unstructured":"Power JR, Alexandre J, Choudhary A, et al.. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. Circulation. 2021, 144:1521-3. 10.1161\/CIRCULATIONAHA.121.055816","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40171","article-title":"Durvalumab-associated myocarditis initially presenting with sinus bradycardia progressing into complete heart block","volume":"15","author":"Bae S","year":"2023","unstructured":"Bae S, Vaysblat M, Ng J, Beccarino N, Makaryus J, Sarkar K. Durvalumab-associated myocarditis initially presenting with sinus bradycardia progressing into complete heart block. Cureus. 2023, 15:e40171. 10.7759\/cureus.40171","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrcr.2020.07.015","article-title":"Complete heart block and subsequent sudden cardiac death from immune checkpoint inhibitor-associated myocarditis","volume":"6","author":"Giancaterino S","year":"2020","unstructured":"Giancaterino S, Abushamat F, Duran J, Lupercio F, DeMaria A, Hsu JC. Complete heart block and subsequent sudden cardiac death from immune checkpoint inhibitor-associated myocarditis. HeartRhythm Case Rep. 2020, 6:761-4. 10.1016\/j.hrcr.2020.07.015","journal-title":"HeartRhythm Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0255-17","article-title":"Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring","volume":"57","author":"Katsume Y","year":"2018","unstructured":"Katsume Y, Isawa T, Toi Y, Fukuda R, Kondo Y, Sugawara S, Ootomo T. Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med. 2018, 57:3157-62. 10.2169\/internalmedicine.0255-17","journal-title":"Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.898756","article-title":"Successful therapy for myocarditis concomitant with complete heart block after pembrolizumab treatment for head and neck squamous cell carcinoma: a case report with literature review","volume":"9","author":"Su L","year":"2022","unstructured":"Su L, Liu C, Wu W, Cui Y, Wu M, Chen H. Successful therapy for myocarditis concomitant with complete heart block after pembrolizumab treatment for head and neck squamous cell carcinoma: a case report with literature review. Front Cardiovasc Med. 2022, 9:898756. 10.3389\/fcvm.2022.898756","journal-title":"Front Cardiovasc Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball S","year":"2019","unstructured":"Ball S, Ghosh RK, Wongsaengsak S, et al.. Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week. J Am Coll Cardiol. 2019, 74:1714-27. 10.1016\/j.jacc.2019.07.079","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030382","article-title":"Antithymocyte globulin inhibits CD8(+) T cell effector functions via the paracrine induction of PDL-1 on monocytes","volume":"12","author":"Copic D","year":"2023","unstructured":"Copic D, Direder M, Klas K, Bormann D, Laggner M, Ankersmit HJ, Mildner M. Antithymocyte globulin inhibits CD8(+) T cell effector functions via the paracrine induction of PDL-1 on monocytes. Cells. 2023, 12:382. 10.3390\/cells12030382","journal-title":"Cells"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra S","year":"2018","unstructured":"Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018, 23:879-86. 10.1634\/theoncologist.2018-0130","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/265607-complete-heart-block-in-a-patient-undergoing-combination-immune-checkpoint-inhibitor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:25:18Z","timestamp":1723562718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/265607-complete-heart-block-in-a-patient-undergoing-combination-immune-checkpoint-inhibitor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.66776","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,13]]}}}